SCM
CTKB icon

Sterling Capital Management’s Cytek Biosciences CTKB Stock Holding History

Sterling Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.1K Sell
3,919
-2,903
-43% -$13.7K ﹤0.01% 2092
2025
Q4 		$34.5K Sell
6,822
-1,291
-16% -$6K ﹤0.01% 1951
2025
Q3 		$28.2K Buy
8,113
+4,921
+154% +$18.5K ﹤0.01% 1986
2025
Q2 		$10.9K Buy
3,192
+1,137
+55% +$3.79K ﹤0.01% 2080
2025
Q1 		$8.24K Sell
2,055
-1,832
-47% -$9.49K ﹤0.01% 1933
2024
Q4 		$25.2K Buy
3,887
+3,455
+800% +$20.6K ﹤0.01% 1804
2024
Q3 		$2.39K Buy
+432
New +$2.45K ﹤0.01% 2101

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sterling Capital Management's CTKB Position: Q1 2026 in Review

Sterling Capital Management reduced its Cytek Biosciences (CTKB) stake by 43% in Q1 2026, selling an estimated $13.7K and leaving 3,919 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

Sterling Capital Management first reported a position in CTKB in Q3 2024 and has held it in 7 quarters since. The position peaked at $34.5K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Sterling Capital Management held 3,919 shares of Cytek Biosciences worth $17.1K as of Q1 2026.
  • Sterling Capital Management sold 2,903 Cytek Biosciences shares in Q1 2026, an estimated $13.7K.
  • Cytek Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2092 holding.
  • Sterling Capital Management first reported a position in Cytek Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Cytek Biosciences position peaked at $34.5K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.